Our Mission

Genmab is dedicated to creating and developing human antibodies to help people suffering from life-threatening and debilitating diseases. Our goal is to serve patients in need of new types of therapy and to build a business that maximizes value for patients and shareholders.

Our Strategy

Genmab's strategy is to maintain an extensive pipeline of human antibody products to balance the risk inherent in drug development and maximize our chances for success. To achieve this goal, we have selected disease targets that have a strong scientific and business rationale. We diversify our potential revenue stream by creating products for an array of both validated and novel targets. We also attempt to balance risk through our partnering efforts by licensing some programs at an early stage and others later to create a potentially diversified risk and revenue profile.

Our Team

The Genmab team is comprised of highly skilled and experienced professionals with the dedication, determination and integrity necessary to succeed in the competitive biotechnology field. Our international teams work closely together to streamline and coordinate product discovery, manufacturing, pre-clinical testing, clinical trial design, data management and regulatory submissions.

Our Product Pipeline

Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. Our pipeline of fully human antibodies currently consists of 10 products in clinical development, over a dozen in pre-clinical development and a dozen other disease targets under exploration. Detailed information on our products can be found on our Products in Development page.

Our Technology

Using the HuMAb-Mouse® transgenic mouse technology licensed from Medarex, Genmab can rapidly create fully human high affinity antibodies which may have less potential to elicit allergic responses or other side effects than previous generations of antibody products which have typically contained mouse or other animal proteins. The HuMAb-Mouse technology, furthermore, eliminates the need for humanization or complicated genetic engineering, which can be time consuming and expensive.

In addition, Genmab has developed UniBody, a proprietary technology which is used to create a smaller antibody format which may offer several advantages over traditional full size monoclonal antibodies. The UniBody's small size means it has better distribution over targeted areas such as large tumors. The UniBody also binds to only one site and does not produce an immune response, making it possible to treat some forms of cancer, inflammation and asthma that other antibodies cannot treat. Click here for more information on the UniBody technology.

Our Development Capabilities

Genmab's pre-clinical development team works diligently to select the best antibody candidates for development. A panel of antibodies is generated and put through a rigorous series of laboratory functional assays designed to identify the characteristics of the best therapeutic product. Following this in vitro testing, the product candidate is evaluated in vivo using animal disease models prior to initiation human clinical trials. Our in house regulatory, clinical development and data management teams then use their international expertise to move Genmab's products through the clinic.
 

Our Manufacturing Capacity

Genmab’s state of the art antibody manufacturing has a production capacity of 22,000 liters, sufficient to provide a sustainable source of clinical and commercial scale material for Genmab’s pipeline.  The facility features two 1,000 liter and two 10,000 liter bioreactors, which support the simultaneous manufacture of multiple antibody products and will enable Genmab to transition three antibodies from research to manufacturing per year.